Does the media favor PYPD or FENC?

In the previous week, PolyPid had 5 more articles in the media than Adherex Technologies. MarketBeat recorded 7 mentions for PolyPid and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.61 beat PolyPid's score of 0.33 indicating that Adherex Technologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment PolyPid 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Adherex Technologies 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BIOA or PYPD more profitable?

PolyPid has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat PolyPid's return on equity. Company Net Margins Return on Equity Return on Assets BioAge Labs -912.26% -28.99% -27.09% PolyPid N/A -311.08% -150.83%

Does the media prefer BIOA or PYPD?

In the previous week, PolyPid had 3 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for PolyPid and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.62 beat PolyPid's score of 0.33 indicating that BioAge Labs is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioAge Labs 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PolyPid 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to ENTA or PYPD?

In the previous week, PolyPid had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 7 mentions for PolyPid and 5 mentions for Enanta Pharmaceuticals. PolyPid's average media sentiment score of 0.33 beat Enanta Pharmaceuticals' score of 0.15 indicating that PolyPid is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Enanta Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PolyPid 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor EYPT or PYPD?

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 7 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.34 beat PolyPid's score of 0.33 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Eyepoint Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral PolyPid 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor VNDA or PYPD?

In the previous week, Vanda Pharmaceuticals had 3 more articles in the media than PolyPid. MarketBeat recorded 10 mentions for Vanda Pharmaceuticals and 7 mentions for PolyPid. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat PolyPid's score of 0.33 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vanda Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral PolyPid 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

PolyPid (PYPD) Competitors

$5.19 -0.18 (-3.35%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.16 -0.03 (-0.48%)

As of 10/2/2026 07:30 PM Eastern

Compare

PYPD vs. FENC, BIOA, ENTA, EYPT, and VNDA

Should you buy PolyPid stock or one of its competitors? PolyPid's main competitors and comparable companies include Adherex Technologies (FENC), BioAge Labs (BIOA), Enanta Pharmaceuticals (ENTA), Eyepoint Pharmaceuticals (EYPT), and Vanda Pharmaceuticals (VNDA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does PolyPid compare to Adherex Technologies?

PolyPid (NASDAQ:PYPD) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, PolyPid had 5 more articles in the media than Adherex Technologies. MarketBeat recorded 7 mentions for PolyPid and 2 mentions for Adherex Technologies. Adherex Technologies' average media sentiment score of 0.61 beat PolyPid's score of 0.33 indicating that Adherex Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PolyPid	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Adherex Technologies	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

PolyPid has a beta of 1.38, indicating that its share price is 38% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, indicating that its share price is 23% more volatile than the broader market.

Adherex Technologies has higher revenue and earnings than PolyPid. Adherex Technologies is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A
Adherex Technologies	$44.64M	8.03	-$9.74M	-$0.13	N/A

PolyPid has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PolyPid	N/A	-311.08%	-150.83%
Adherex Technologies	-6.09%	-5.71%	-2.37%

PolyPid presently has a consensus price target of $11.33, indicating a potential upside of 118.37%. Adherex Technologies has a consensus price target of $17.00, indicating a potential upside of 66.67%. Given PolyPid's higher possible upside, equities analysts plainly believe PolyPid is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

26.5% of PolyPid shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 24.7% of PolyPid shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Adherex Technologies beats PolyPid on 8 of the 14 factors compared between the two stocks.

How does PolyPid compare to BioAge Labs?

BioAge Labs (NASDAQ:BIOA) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

BioAge Labs has a beta of 1.08, indicating that its stock price is 8% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

PolyPid has lower revenue, but higher earnings than BioAge Labs. PolyPid is trading at a lower price-to-earnings ratio than BioAge Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioAge Labs	$8.99M	33.75	-$80.61M	-$2.38	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

PolyPid has a net margin of 0.00% compared to BioAge Labs' net margin of -912.26%. BioAge Labs' return on equity of -28.99% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioAge Labs	-912.26%	-28.99%	-27.09%
PolyPid	N/A	-311.08%	-150.83%

BioAge Labs currently has a consensus price target of $36.57, indicating a potential upside of 453.27%. PolyPid has a consensus price target of $11.33, indicating a potential upside of 118.37%. Given BioAge Labs' stronger consensus rating and higher possible upside, equities research analysts plainly believe BioAge Labs is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, PolyPid had 3 more articles in the media than BioAge Labs. MarketBeat recorded 7 mentions for PolyPid and 4 mentions for BioAge Labs. BioAge Labs' average media sentiment score of 0.62 beat PolyPid's score of 0.33 indicating that BioAge Labs is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioAge Labs	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PolyPid	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

26.5% of PolyPid shares are held by institutional investors. 17.6% of BioAge Labs shares are held by company insiders. Comparatively, 24.7% of PolyPid shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

BioAge Labs beats PolyPid on 8 of the 15 factors compared between the two stocks.

How does PolyPid compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their media sentiment, risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.

In the previous week, PolyPid had 2 more articles in the media than Enanta Pharmaceuticals. MarketBeat recorded 7 mentions for PolyPid and 5 mentions for Enanta Pharmaceuticals. PolyPid's average media sentiment score of 0.33 beat Enanta Pharmaceuticals' score of 0.15 indicating that PolyPid is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enanta Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PolyPid	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Enanta Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

Enanta Pharmaceuticals currently has a consensus price target of $19.00, indicating a potential upside of 46.60%. PolyPid has a consensus price target of $11.33, indicating a potential upside of 118.37%. Given PolyPid's higher probable upside, analysts clearly believe PolyPid is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

PolyPid has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than PolyPid, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.78	-$81.89M	-$2.41	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

PolyPid has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Enanta Pharmaceuticals' return on equity of -61.84% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
PolyPid	N/A	-311.08%	-150.83%

95.0% of Enanta Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 11.5% of Enanta Pharmaceuticals shares are owned by insiders. Comparatively, 24.7% of PolyPid shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

PolyPid beats Enanta Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

How does PolyPid compare to Eyepoint Pharmaceuticals?

Eyepoint Pharmaceuticals (NASDAQ:EYPT) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.

In the previous week, Eyepoint Pharmaceuticals and Eyepoint Pharmaceuticals both had 7 articles in the media. Eyepoint Pharmaceuticals' average media sentiment score of 0.34 beat PolyPid's score of 0.33 indicating that Eyepoint Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eyepoint Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
PolyPid	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Eyepoint Pharmaceuticals currently has a consensus price target of $25.70, suggesting a potential upside of 690.77%. PolyPid has a consensus price target of $11.33, suggesting a potential upside of 118.37%. Given Eyepoint Pharmaceuticals' higher possible upside, research analysts clearly believe Eyepoint Pharmaceuticals is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eyepoint Pharmaceuticals	1 Sell rating(s)	6 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.27
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

99.4% of Eyepoint Pharmaceuticals shares are owned by institutional investors. Comparatively, 26.5% of PolyPid shares are owned by institutional investors. 5.1% of Eyepoint Pharmaceuticals shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Eyepoint Pharmaceuticals has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, PolyPid has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

PolyPid has a net margin of 0.00% compared to Eyepoint Pharmaceuticals' net margin of -10,994.73%. Eyepoint Pharmaceuticals' return on equity of -135.81% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eyepoint Pharmaceuticals	-10,994.73%	-135.81%	-108.35%
PolyPid	N/A	-311.08%	-150.83%

PolyPid has lower revenue, but higher earnings than Eyepoint Pharmaceuticals. PolyPid is trading at a lower price-to-earnings ratio than Eyepoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eyepoint Pharmaceuticals	$31.37M	8.93	-$231.96M	-$3.74	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

Summary

Eyepoint Pharmaceuticals beats PolyPid on 9 of the 14 factors compared between the two stocks.

How does PolyPid compare to Vanda Pharmaceuticals?

Vanda Pharmaceuticals (NASDAQ:VNDA) and PolyPid (NASDAQ:PYPD) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Vanda Pharmaceuticals has a beta of 0.69, indicating that its stock price is 31% less volatile than the broader market. Comparatively, PolyPid has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market.

88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 26.5% of PolyPid shares are held by institutional investors. 10.7% of Vanda Pharmaceuticals shares are held by insiders. Comparatively, 24.7% of PolyPid shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

PolyPid has lower revenue, but higher earnings than Vanda Pharmaceuticals. PolyPid is trading at a lower price-to-earnings ratio than Vanda Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals	$216.10M	1.30	-$220.47M	-$4.63	N/A
PolyPid	N/A	N/A	-$34.17M	-$1.48	N/A

PolyPid has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -127.41%. Vanda Pharmaceuticals' return on equity of -49.81% beat PolyPid's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals	-127.41%	-49.81%	-33.29%
PolyPid	N/A	-311.08%	-150.83%

Vanda Pharmaceuticals currently has a consensus target price of $13.08, suggesting a potential upside of 182.58%. PolyPid has a consensus target price of $11.33, suggesting a potential upside of 118.37%. Given Vanda Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Vanda Pharmaceuticals is more favorable than PolyPid.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vanda Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56
PolyPid	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, Vanda Pharmaceuticals had 3 more articles in the media than PolyPid. MarketBeat recorded 10 mentions for Vanda Pharmaceuticals and 7 mentions for PolyPid. Vanda Pharmaceuticals' average media sentiment score of 0.46 beat PolyPid's score of 0.33 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vanda Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
PolyPid	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Vanda Pharmaceuticals beats PolyPid on 10 of the 15 factors compared between the two stocks.

Get PolyPid News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PYPD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PYPD vs. The Competition

Export

Metric	PolyPid	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$99.04M	$12.24B	$7.16B	$13.28B
Dividend Yield	N/A	2.64%	2.54%	17.32%
P/E Ratio	-3.51	799.70	275.66	26.04
Price / Sales	N/A	752.91	609.44	91.76
Price / Cash	N/A	86.66	78.87	52.62
Price / Book	7.52	10.46	10.93	6.31
Net Income	-$34.17M	$2.84B	$3.51B	$362.16M
7 Day Performance	-0.57%	-1.57%	-2.00%	-1.66%
1 Month Performance	-1.52%	-5.67%	-6.15%	-4.50%
1 Year Performance	48.29%	-4.73%	7.44%	2.06%

PolyPid Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PYPD PolyPid	2.9173 of 5 stars	$5.19 -3.4%	$11.33 +118.4%	+50.0%	$99.04M	N/A	N/A	75	News Coverage High Trading Volume
FENC Adherex Technologies	3.9838 of 5 stars	$11.01 +0.9%	$17.00 +54.4%	+5.5%	$382.49M	$44.64M	N/A	35
BIOA BioAge Labs	3.0594 of 5 stars	$8.46 +4.6%	$36.57 +332.3%	+12.0%	$371.31M	$8.99M	N/A	62
ENTA Enanta Pharmaceuticals	1.7692 of 5 stars	$12.42 +2.6%	$21.00 +69.1%	+25.5%	$352.71M	$65.32M	N/A	120	News Coverage Analyst Upgrade
EYPT Eyepoint Pharmaceuticals	2.8604 of 5 stars	$4.07 +1.2%	$25.70 +531.4%	-75.9%	$346.57M	$31.37M	N/A	214	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PYPD) was last updated on 10/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PolyPid (PYPD) Competitors

PYPD vs. FENC, BIOA, ENTA, EYPT, and VNDA

How does PolyPid compare to Adherex Technologies?

Summary

How does PolyPid compare to BioAge Labs?

Summary

How does PolyPid compare to Enanta Pharmaceuticals?

Summary

How does PolyPid compare to Eyepoint Pharmaceuticals?

Summary

How does PolyPid compare to Vanda Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PolyPid (PYPD) Competitors

PYPD vs. FENC, BIOA, ENTA, EYPT, and VNDA

How does PolyPid compare to Adherex Technologies?

Does the media favor PYPD or FENC?

Which has more risk and volatility, PYPD or FENC?

Which has better earnings and valuation, PYPD or FENC?

Is PYPD or FENC more profitable?

Do analysts recommend PYPD or FENC?

Do insiders and institutionals believe in PYPD or FENC?

Summary

How does PolyPid compare to BioAge Labs?

Which has more risk and volatility, BIOA or PYPD?

Which has stronger valuation & earnings, BIOA or PYPD?

Is BIOA or PYPD more profitable?

Do analysts prefer BIOA or PYPD?

Does the media prefer BIOA or PYPD?

Do institutionals & insiders believe in BIOA or PYPD?

Summary

How does PolyPid compare to Enanta Pharmaceuticals?

Does the media refer more to ENTA or PYPD?

Which has more volatility and risk, ENTA or PYPD?

Do analysts rate ENTA or PYPD?

Which has preferable valuation & earnings, ENTA or PYPD?

Is ENTA or PYPD more profitable?

Do institutionals and insiders believe in ENTA or PYPD?

Summary

How does PolyPid compare to Eyepoint Pharmaceuticals?

Does the media favor EYPT or PYPD?

Do analysts rate EYPT or PYPD?

Do institutionals and insiders hold more shares of EYPT or PYPD?

Which has more volatility & risk, EYPT or PYPD?

Is EYPT or PYPD more profitable?

Which has higher earnings & valuation, EYPT or PYPD?

Summary

How does PolyPid compare to Vanda Pharmaceuticals?

Which has more volatility and risk, VNDA or PYPD?

Do insiders and institutionals have more ownership in VNDA or PYPD?

Which has better earnings and valuation, VNDA or PYPD?

Is VNDA or PYPD more profitable?

Do analysts recommend VNDA or PYPD?

Does the media favor VNDA or PYPD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYPD vs. The Competition

PolyPid Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools